Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06876064

National Cohort of Subjects at Risk of Developing Rheumatoid Arthritis

Sponsor: University Hospital, Montpellier

View on ClinicalTrials.gov

Summary

PROMESS 1 is a multicenter cohort interventional study aiming at analyzing the factors associated with the risk of developing clinical arthritis among exposures or combinations of exposures in patients at risk of rheumatoid arthritis (RA), as they have high levels of anti-citrullinated peptides autoantibodies (ACPA ≥2 N). The primary endpoint is the occurrence of clinical arthritis confirmed by ultrasound at two years of following for the subject's groups at risk of RA. This may be explained by the following exposures or combinations of exposures: smoking, occupational exposure, physical activity, diet, hormonal exposure, drug exposure, trauma and psychological stress. Other factors may also explain the occurrence of clinical arthritis: * Other symptoms * Comorbidities, medical history, drug exposures * Current biology: ACPA levels, rheumatoid factor levels and isotypes, CRP levels at baseline, etc. * Ultrasound and MRI abnormalities.

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

OBSERVATIONAL

Enrollment

150

Start Date

2025-10

Completion Date

2027-12

Last Updated

2025-10-01

Healthy Volunteers

Yes

Interventions

BIOLOGICAL

Blood test

A total of 60 ml of blood will be collected while fasting, using the following tubes: one PAXGene Blood RNA Tube, one PAXGene Blood DNA Tube, five 5 mL serum tubes, five 5 mL EDTA tubes and one 2 mL EDTA tube for microbiota DNA analysis.

BIOLOGICAL

Urine test

Urine will be collected, while fasting and after the administration of lactulose/ mannitol to assess intestinal permeability.

OTHER

stool collection

Stool samples will be collected either at the hospital or at home using a dedicated kit.

OTHER

saliva collection

5 ml of saliva will be collected and saliva microbiome DNA will be collected using an OMNIgene Oral kit.

OTHER

Induced expectoration

inhalation of salbutamol, measurement of peak expiratory flow by screening spirometry (15 min later), inhalation of a hypertonic aerosol for 3 periods of 7 min. At the end of each inhalation period, the induced sputum is collected and the peak expiratory flow is measured to prevent possible bronchospasms

OTHER

Hair and nails sampling

Hair and nails samples will be collected.

OTHER

Schirmer test

To assess of tear secretion

RADIATION

Ultrasound of hands and feet

To assess the risk of RA in high-risk subjects by evaluating for synovitis, tenosynovitis, or intermetatarsal-phalangeal bursitis.

RADIATION

MRI Contrast

MRI of the dominant or painful hand will be performed to assess the risk of RA in high-risk subjects.

OTHER

Patient questions

Self-questionnaires will assess factors such as ethnic origin, family history of RA, diet, physical activity, exposure to toxic substances, pollution, occupational exposures, psychological and clinical factors.

DIAGNOSTIC_TEST

Dental panoramic X-ray

Performed as part of routine care to assess dental health

OTHER

Consultation with a psychologist in certain centers

The short-CTQ will be completed during this consultation, only in centers offering consultations with a psychologist.

OTHER

Measurement of heart rate variability.

The patient will wear a belt throughout the visit 1. At the end of the day, the heart rate variability data measured by the belt will be recorded in the CRF (RR interval, heart rate variability SDNN, RMSSD, and LF/HF sympathovagal balance).

Locations (1)

CHU Montpellier

Montpellier, Hérault, France